Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy

Experimental Cell Research

Volumn 245, Issue 2, 1998, Pages 350-359

  Ohmori, Tohru ^a,d   Yang, Jin Long ^a   Price, James O ^a,b,c   Arteaga, Carlos L ^a,b,c,e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d SHOWA UNIVERSITY   (Japan)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

Apoptosis; Breast carcinoma; Cell cycle; Cisplatin; Spheroids; Transforming growth factor

Indexed keywords

CISPLATIN; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CELL CYCLE; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0032534450     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.4261     Document Type: Article

References (57)

1. Moses H. L. The biological action of transforming growth factor β Growth Factors from Genes to Clinical Application. 1990;Raven Press, New York. p. 141-155.
2. Roberts, A. B. Sporn, M. B. 1990, The transforming growth factor-βs, In, Handbook of Experimental Pharmacology, 95, 419-472, Springer-Verlag, Heidelberg.
3. Alexandrow M. G., Moses H. L. Transforming growth factor β and cell cycle regulation. Cancer Res. 55:1995;1452-1457.
4. Koli K. M., Arteaga C. L. Complex role of tumor cell transforming growth factor (TGF)-βs on breast carcinoma progression. J. Mammary Gland Biol. & Neopl. 1:1996;373-380.
5. Brattain M. G., Ko Y., Banerji S. S., Wu G., Willson J. K. V. Defects of TGF-β receptor signaling in mammary cell tumorigenesis. J. Mammary Gland Biol. Neopl. 1:1996;365-372.
6. 1. Cancer Res. 52:1992;6949-6952.
7. 1. Br. J. Cancer. 63:1991;609-614.
8. Baillie R., Coombes R. C., Smith J. Multiple forms of TGF-β in breast tissue: A biologically active form of the small latent complex of TGF-β1. Eur. J. Cancer. 32A:1996;1566-1573.
9. Teicher B. A., Holden S. A., Ara G., Chen G. Transforming growth factor-β in in vivo resistance. Cancer Chemother. Pharmacol. 37:1996;601-609.
10. Teicher B. A., Maehara Y., Kakeji Y., Ara G., Keyes S. R., Wong Y., Herbst R. Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Int. J. Cancer. 71:1997;49-58.
11. Teicher B. A., Herman T. S., Holden S. A., Wang Y., Pfeffer M. R., Crawford J. M., Frei E. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 247:1990;1457-1461.
12. Kobayashi H., Man S., Graham C. H., Kapitain S. J., Teicher B. A., Kerbel R. S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA. 90:1993;3294-3298.
13. Cailleau R., Young R., Olive M., Reeves W. J. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:1974;661-674.
14. Arrick B. A., Korc M., Derynck R. Differential regulation of expression of three transforming growth factor β species in human breast cancer cell lines by estradiol. Cancer Res. 50:1990;299-303.
15. Arteaga C. L., Coffey R. J., Dugger T. C., McCutchen C. M., Moses H. L., Lyons R. M. Growth stimulation of breast cancer cells with anti-transforming growth factor β antibodies: Evidence for negative autocrine growth regulation by transforming growth factor β Cell Growth Differ. 1:1990;367-374.
16. Arteaga C. L., Hurd S. D., Winnier A. R., Johnson M. D., Fendly B. M., Forbes J. T. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Invest. 92:1993;2569-2576.
17. 1. J. Immunol. 145:1990;1415-1422.
18. 1. Mol. Cell. Biol. 14:1994;2077-2086.
19. Wang T. T. Y., Phang J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 55:1995;2487-2489.
20. Koli K. M., Arteaga C. L. Predominant cytosolic localization of type II transforming growth factor β receptors in human breast carcinoma cells. Cancer Res. 57:1997;970-977.
21. Derynck R., Jarrett J. A., Chen E. Y., Eaton D. H., Bell J. R., Assoian R. K., Roberts A. B., Sporn M. B., Goeddel D. V. Human transforming growth factor-beta cDNA sequence and expression in tumor cell lines. Nature. 316:1985;701-705.
22. Fang F., Orend G., Watanabe N., Hunter T., Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 271:1996;499-502.
23. Kip1. Nature Med. 2:1996;1204-1210.
24. Kerbel R. S., Rak J., Kobayashi H., Man M. S., St. Croix B., Graham C. H. Multicellular resistance: A new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harbor Symp. Quant. Biol. 59:1994;661-672.
25. Hoffman R. M. To do tissue culture in two or three dimensions? That is the question. Stem Cells. 11:1993;105-111.
26. Kakeji Y., Maehara Y., Ikebe M., Teicher B. A. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1115-1123.
27. Barcellos-Hoff M. H. Latency and activation in the control of TGF-β J. Mammary Gland Biol. Neopl. 1:1996;353-363.
28. Anscher M. S., Peters W. P., Reisenbichler H., Petros W. P., Jirtle R. L. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N. Engl. J. Med. 328:1993;1592-1598.
29. Iavarone A., Masague J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature. 387:1997;417-422.
30. St. Croix B., Rak J. W., Kapitain S., Sheehan C., Graham C. H., Kerbel R. S. Reversal by hyaluronidase of adhesion dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88:1996;1285-1296.
31. Frankel A., Buckman R., Kerbel R. S. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 57:1997;2388-2393.
32. Tannock I. F. Cell Proliferation. Tannock I. F., Hill R. P. The Basic Science of Oncology. 1992;154-177 McGraw-Hill, New York.
33. Sutherland R. M. Cell and environment interactions in tumor microregions: The multicellular spheroid model. Science. 240:1988;177-184.
34. Nederman T., Norling B., Glimelius B., Carlsson J., Brunk U. Demonstration of an extracellular matrix in multicellular tumor spheroids. Cancer Res. 44:1984;3090-3097.
35. Hoffman R. M. In vitro assays for chemotherapy sensitivity. Crit. Rev. Oncol. Hematol. 15:1993;99-111.
36. Furukawa T., Kubota T., Watanabe M., Takahara T., Yamaguchi H., Takeuchi T., Kase S., Kodaira S., Ishibiki K., Kitajima M., Hoffman R. M. High in vitro-in vivo correlation of drug response using sponge-gel supported three-dimensional histoculture and the MTT end point. Int. J. Cancer. 51:1992;489-498.
37. Yingling J. M., Wang X.-F., Bassing C. H. Signaling by the transforming growth factor-β receptors. Biochim. Biophys. Acta. 1242:1995;115-136.
38. Mendonca M. S., Rodriguez A., Alpen E. L. Differential repair of potentially lethal damage in exponentially growing and quiescent 9L cells. Radiat. Res. 122:1990;38-43.
39. 1. Cancer Res. 51:1991;2379-2385.
40. Smith M. L., Chen I.-T., Zhang Q., O'Connor P. M., Fornace A. J. Involvement of the p53 tumor suppressor gene in repair of u.v.-type DNA damage. Oncogene. 10:1995;1053-1059.
41. Xu C., Meikrantz W., Schlegel R., Sager R. The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis by DNA damage. Proc. Natl. Acad. Sci. USA. 92:1995;7829-7833.
42. Fan S., Smith M. L., Rivet D. J. II, Duba D., Zhan Q., Kohn K. W., Fornace A. J. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55:1995;1649-1654.
43. Waldman T., Lengauer C., Kinzler K. W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
44. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nature Med. 3:1997;1034-1036.
45. Brifford M., Spyratos F., Hacene K., Tubiana-Holin M., Pallud C., Gilles F., Rouesse J. Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis. Cytometry. 13:1992;250-258.
46. Remvikos Y., Jouve M., Beuzeboc P., Viehl P., Magdelenat H., Pouillart P. Cell cycle modifications of breast cancer during neoadjuvant chemotherapy: A flow cytometry study of fine needle aspirates. Eur. J. Cancer. 29A:1993;1843-1848.
47. Daidone M. G., Silvestrini R., Luisi A., Mastore M., Benini E., Veneroni S., Brambilla C., Ferrari L., Greco M., Andreola S., Veronesi U. Changes in biological markers after primary chemotherapy for breast cancers. Int. J. Cancer. 61:1995;301-305.
48. Engelholm S. A., Spang-Thomsen M., Vindelov L. L., Brunner N. A. Chemosensitivity of human small cell carcinoma of the lung detected by flow cytometric DNA analysis of drug-induced cell cycle perturbations in vitro. Cytometry. 7:1986;243-250.
49. Schluesener H. J., Meyermann R. Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type β Acta Neuropathol. 81:1991;641-648.
50. 1. Cancer Res. 55:1995;1758-1762.
51. Sachsenmeier K. F., Sheibani N., Schlosser S. J., Allen-Hoffmann B. L. Transforming growth factor-β1 inhibits nucleosomal fragmentation in human keratinocytes following loss of adhesion. J. Biol. Chem. 271:1996;5-2718.
52. Newman M. J. Transforming growth factor beta and the cell surface in tumor progression. Cancer Metastasis Rev. 12:1993;239-254.
53. Nathan C., Sporn M. B. Cytokines in context. J. Cell Biol. 113:1991;981-986.
54. Arrick B. A., Lopez A. R., Elfman F., Ebner R., Damsky C. H., Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J. Cell Biol. 118:1992;715-726.
55. Fridman R., Giaccone G., Kanemoto T., Martin G. R., Gazdar A. F., Mulshine J. L. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA. 87:1990;6698-6702.
56. Dimanche-Boitrel M.-T., Pelletier H., Genne P., Petit J.-M., Le Grimellec C., Canal P., Ardiet C., Bastian G., Chauffert B. Confluence-dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int. J. Cancer. 50:1992;677-682.
57. Saiki I., Yoneda J., Kobayashi H., Igarashi Y., Komazawa H., Ishizaki Y., Kato I., Azuma I. Antimetastatic effect of anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. Jpn. J. Cancer Res. 84:1993;326-335.